knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 11:09:09 - browse：3474

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： AI gets buy

WSS

Gritstone Bio's cancer vaccine test, and more on Novartis' deal

Recent heat wave in the Mediterranean caused by climate change: Study

What’s missing from the debate over nursing home staff minimums

Judge agrees to delay next hearing in Trump classified documents case

The CDC's new social media misinformation war

Pandemic and All Hazards Preparedness Act needs lean update

knowledge

knowledge

hotspot

Medicare details structure of new drug price negotiation program

ACA's risk program benefits Blue Cross Blue Shield insurers

Sports medicine is finally prioritizing gender equality

White House announces new plan to address the growing threat of xylazine in overdose crisis

Wildfire smoke exposes gaps in outdoor worker protections

A single Democrat is willing to weaken Medicare negotiation power

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Texas Medical Board asked to define abortion emergency exception

Duchenne breakthrough therapy leaves behind pioneering families

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

focus

Cano Health’s bankruptcy is a warning for Medicare Advantage

Swim instructor mom warns parents not to buy blue swimsuits for kids

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Readout Newsletter: Amgen, Regeneron, BGI Group and more

Why Novartis is going to walk from its acquisition of MorphoSys

340B reform proposal comes out of Senate working group

Wikipedia

hotspot

focus

entertainment